Bausch + Lomb (NYSE:BLCO) EVP Acquires $250,390.00 in Stock

Bausch + Lomb Corporation (NYSE:BLCO) EVP A Robert Bailey bought 14,600 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average price of $17.15 per share, for a total transaction of $250,390.00. Following the completion of the purchase, the executive vice president owned 231,890 shares in the company, valued at $3,976,913.50. The trade was a 6.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bausch + Lomb Stock Down 0.6%

NYSE:BLCO traded down $0.10 during mid-day trading on Tuesday, hitting $17.12. 201,504 shares of the company’s stock traded hands, compared to its average volume of 402,941. The company has a fifty day moving average of $17.28 and a 200 day moving average of $16.17. Bausch + Lomb Corporation has a twelve month low of $10.45 and a twelve month high of $18.92. The company has a market capitalization of $6.06 billion, a P/E ratio of -16.78, a P/E/G ratio of 0.72 and a beta of 0.58. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.04 and a current ratio of 1.55.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03). Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.38 billion. During the same period in the prior year, the business posted $0.25 EPS. Bausch + Lomb’s revenue was up 9.8% compared to the same quarter last year. On average, analysts forecast that Bausch + Lomb Corporation will post 0.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $18.00 target price on shares of Bausch + Lomb in a research note on Thursday, February 19th. Stifel Nicolaus set a $16.00 price target on shares of Bausch + Lomb in a report on Thursday, February 19th. Wells Fargo & Company lifted their price objective on shares of Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, January 21st. Finally, Barclays upped their target price on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $18.25.

Institutional Trading of Bausch + Lomb

Several institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its holdings in shares of Bausch + Lomb by 428.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after acquiring an additional 242,993 shares during the last quarter. Woodline Partners LP raised its holdings in shares of Bausch + Lomb by 0.5% during the first quarter. Woodline Partners LP now owns 312,823 shares of the company’s stock worth $4,536,000 after purchasing an additional 1,436 shares during the last quarter. Fountainhead AM LLC acquired a new position in Bausch + Lomb during the second quarter valued at $193,000. Kazazian Asset Management LLC acquired a new position in Bausch + Lomb during the second quarter valued at $722,000. Finally, Handelsbanken Fonder AB purchased a new stake in Bausch + Lomb in the second quarter valued at $202,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.